Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki Disease

New England Journal of Medicine

Volumn 356, Issue 7, 2007, Pages 663-675

  Newburger, Jane W ^a   Sleeper, Lynn A ^b   McCrindle, Brian W ^c   Minich, LuAnn ^d   Gersony, Welton ^e   Vetter, Victoria L ^f   Atz, Andrew M ^g   Li, Jennifer S ^h   Takahashi, Masato ⁱ   Baker, Annette L ^a   Colan, Steven D ^a   Mitchell, Paul D ^b   Klein, Gloria L ^b   Sundel, Robert P ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO;

ADD ON THERAPY; ANAPHYLAXIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HUMAN; HYPOKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTICENTER STUDY; PERCEPTION DEAFNESS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SHOCK;

EID: 33846995989     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa061235     Document Type: Article

References (33)

1. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71.
2. Dajani AS, Taubert KA, Takahashi M, et al. Guidelines for long-term management of patients with Kawasaki disease: report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994;89:916-22.
3. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93.
4. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immune globulin treatment. Pediatrics 1995;96:1057-61.
5. de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998;133:254-8.
6. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
7. Newburger JW. Treatment of Kawasaki disease: corticosteroids revisited. J Pediatr 1999;135:411-3.
8. Kijima Y, Kamiya T, Suzuki A, Hirose O, Manabe H. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ J 1982;46:1239-42.
9. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9.
10. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999;135:465-9.
11. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. Pediatrics 2005;116:989-95.
12. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006;149:336-41.
13. Mahony L, Sleeper LA, Anderson PA, et al. The Pediatric Heart Network: a primer for the conduct of multicenter studies in children with congenital and acquired heart disease. Pediatr Cardiol 2006;27:191-8.
14. Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo: Ministry of Health and Welfare, 1984.
15. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003;142:611-6.
16. Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003;143:363-7.
17. Kan Z, Hashino K. Effectiveness of steroid-aspirin combined therapy for Kawasaki disease. J Pediatr Pract 1990;53:328-31.
18. Kusakawa S. Long-term administrative care of Kawasaki disease. Acta Paediatr Jap 1983;25:205-9.
19. Neudorf U. New therapeutic aspects in Kawasaki syndrome and personal experiences. Infusionsther Transfusionsmed 1993;20:Suppl 1:137-9. (In German.)
20. Sone K, Suzuiku A. Multidrug therapy for MCLS. J Pediatr Pract 1987;50:1175-80.
21. Ioannidis JP, Cappelleri JC, Lau J. Issues in comparisons between meta-analyses and large trials. JAMA 1998;279:1089-93.
22. Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized, controlled trials: examples from the management of acute myocardial infarction. Ann Intern Med 1995;123:873-7.
23. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
24. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immune globulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40.
25. Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T. Risk factors associated with the need for additional intravenous gammaglobulin therapy for Kawasaki disease. Acta Paediatr 2006;95:189-93.
26. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immune globulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12.
27. Ito S, Kusunoki Y, Oka T, Ito Y, Okuno A, Yoshioka H. Pharmacokinetics of high-dose methylprednisolone in children. Dev Pharmacol Ther 1992;19:99-105.
28. Suzuki N, Seguchi M, Kouno C, Inukai K, Kito H, Kobayashi H. Rupture of coronary aneurysm in Kawasaki disease. Pediatr Int 1999;41:318-20.
29. Imai Y, Momma K, eds. Pathological study of ruptured coronary artery aneurysms of Kawasaki disease. New York: Futura, 1997.
30. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-7.
31. Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J Pediatr 2003;142:601-3.
32. Dale RC, Saleem MA, Daw S, Dillon MJ. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr 2000;137:723-6.
33. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78.